Actively Recruiting
Cardiopulmonary Bypass Induced Red Blood Cell Lysis
Led by University of Maryland, Baltimore · Updated on 2025-08-19
150
Participants Needed
1
Research Sites
297 weeks
Total Duration
On this page
Sponsors
U
University of Maryland, Baltimore
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Studying the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB. These results will be compared to existing laboratory-based methods for determining red blood cell damage to predict CPB assist device safety. Further, results from the studies described in this proposal will help develop therapeutic strategies to benefit patients by early detection of pfH and clearance protein levels that occur during CPB.
CONDITIONS
Official Title
Cardiopulmonary Bypass Induced Red Blood Cell Lysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Admitted to UMMC for cardiac procedure
- Age between 18 and 88 years old
- Undergoing cardiopulmonary bypass for more than 1 hour during complex cardiac surgery, heart valve replacement, or CABG surgery
You will not qualify if you...
- Pregnant
- Non English speaking
- Unable to consent or have a legally authorized representative to assent to the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for Blood Oxygen Transport and Hemostasis
Baltimore, Maryland, United States, 21201
Actively Recruiting
Research Team
P
Paul W Buehler, PhD
CONTACT
T
Tobi Rowden, RN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here